GENOMIC LANDSCAPE AND ACTIONABLE MUTATIONS OF BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW

Abstract AIMS Lung cancer causes the most deaths worldwide due to cancer. Non-small cell lung (NSCLC) represents largest subgroup (80-90%), with patients presenting at an advanced stage of disease. Brain metastases (BM) develop in about 27% these cases, leading a poor survival outcome. Previous literature has suggested that BM derived from NSCLC have different genomic profile compared primary NSCLC. We aim review discover landscape METHOD Embase, MEDLINE, Web Science, and BIOSIS were searched, any records found assessed for eligibility. For included papers, patient information, smoking status, data, matched NSCLC, PD-L1 expression was extracted. RESULTS 72 papers review, data on 2,340 patients. The mutated genes EGFR (n=560), TP53 (n=331), KRAS (n=328), CDKN2A (n=97), STK11 (n=72). Frequently missense mutations L858R (n=80) G12C (n=17) KRAS. Ever versus never smokers differing mis- sense EGFR, expectation T790M. be low CONCLUSIONS To our knowledge, this is first systematic which This highlights genes, mutations, their clinical actionability. Differing profiles status.